MiR-129-5p Suppresses Cell Proliferation of Human Osteosarcoma Cancer by Down-Regulating LncRNA Lnc712
Authors Yu Y, Zuo W, Cai W, Xu Y, Liu W, Zhao Z
Received 14 October 2020
Accepted for publication 14 February 2021
Published 10 March 2021 Volume 2021:13 Pages 2259—2264
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Eileen O'Reilly
Yifan Yu, Wenshan Zuo, Wei Cai, Yong Xu, Weidong Liu, Zexue Zhao
Department of Orthopaedics, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an City, Nanjing Province, 223300, People’s Republic of China
Correspondence: Wenshan Zuo
Department of Orthopaedics, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, No. 1 Huanghe West Road, Huaiyin District, Huai’an City, Nanjing Province, 223300, People’s Republic of China
Email [email protected]
Introduction: Lnc712 has been characterized as an oncogenic lncRNA in breast cancer. This study aimed to investigate the role of Lnc712 in osteosarcoma (OS).
Methods: OS and paired non-tumor tissues were collected from 58 OS patients. Expression of Lnc712 and miR-129-5p in paired tissue samples was determined by RT-qPCR. Lnc712 and miR-129-5p expression was achieved in OS cells to study the interaction between them. Cell proliferation was analyzed by CCK-8 assay.
Results: Lnc712 was upregulated in OS and was inversely correlated with miR-129-5p. In OS cells, Lnc712 overexpression failed to significantly affect miR-129-5p, while miR-129-5p overexpression led to downregulated Lnc712. Cell proliferation showed that Lnc712 overexpression resulted in increased cell proliferation rate. MiR-129-5p overexpression played an opposite role and reversed the effect of Lnc712 overexpression.
Discussion: MiR-129-5p may suppress cell proliferation of OS by down-regulating Lnc712.
Keywords: Lnc712, osteosarcoma, miR-129-5p, proliferation
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]